Qualigen therapeutics announces poster featuring positive early clinical experience with qn-302, a novel first-in-class g-quadruplex experimental anti-cancer drug, at the american association of cancer research (aacr) 2024 annual meeting

Carlsbad, calif., april 09, 2024 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or the “company,” nasdaq: qlgn) today announces that a poster featuring its early clinical experience with a novel first-in-class g-quadruplex experimental anti-cancer drug, qn-302, was presented at the american association for cancer research (aacr) annual meeting 2024 held april 5 – 10 in san diego, california.
QLGN Ratings Summary
QLGN Quant Ranking